Sanofi SNY announced preliminary data from the phase II TIDE-Asthma study, which evaluated its anti-OX40L mAb, amlitelimab, ...

Yesafili, a vascular endothelial growth factor inhibitor, is used to treat several different types of ophthalmology ...

Regeneron aims for FDA approval of extended dosing for EYLEA HD in AMD and DME, with a decision by April 2025. Pre-filled ...

With a market cap of $62.4 billion, Regeneron Pharmaceuticals, Inc. (REGN) discovers, invents, develops, manufactures, and ...

The city’s pharmaceutical industry remained stable on Tuesday as federal officials signaled that tariffs could be around the ...

AD is a growing market with an impressive pipeline of new products from current and future players in the field.

Regeneron's oncology platform is poised to be a significant growth driver in the next decade. Read why REGN stock remains a ...

F M Investments boosted its stake in Regeneron Pharmaceuticals by 8.5% in Q4, grabbing 7,003 shares worth nearly $5 million.

Attovia Therapeutics has completed an oversubscribed $90 million Series C financing, which the company plans to use along with existing cash and investments to advance its two lead pipeline candidates ...

High school senior Matteo Paz stunned the astronomy world by uncovering 1.5 million previously unknown cosmic objects using a ...

The stock's fall snapped a two-day winning streak.

Bristol Myers' Camzyos missed goals in a Phase 3 nHCM trial, showing no significant benefits over placebo but raised no new ...